These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 26056328)

  • 1. Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes.
    Ichioka D; Miyazaki J; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Nishiyama H
    Jpn J Clin Oncol; 2015 Sep; 45(9):867-73. PubMed ID: 26056328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
    Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
    Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine Plus Cisplatin Split
    Izumi K; Iwamoto H; Yaegashi H; Shigehara K; Nohara T; Kadono Y; Mizokami A
    In Vivo; 2019; 33(1):167-172. PubMed ID: 30587618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience.
    Kikuchi E; Miyazaki J; Yuge K; Hagiwara M; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Yamamoto S; Kinoshita H; Wakeda H; Hanai K; Nishiyama H
    Jpn J Clin Oncol; 2016 Feb; 46(2):163-9. PubMed ID: 26657277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
    Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
    Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
    Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
    Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
    Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
    J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
    De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Skoneczna I; Marreaud S; de Wit R; Sylvester R
    J Clin Oncol; 2009 Nov; 27(33):5634-9. PubMed ID: 19786668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
    Halim A; Abotouk N
    Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
    Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
    von der Maase H; Hansen SW; Roberts JT; Dogliotti L; Oliver T; Moore MJ; Bodrogi I; Albers P; Knuth A; Lippert CM; Kerbrat P; Sanchez Rovira P; Wersall P; Cleall SP; Roychowdhury DF; Tomlin I; Visseren-Grul CM; Conte PF
    J Clin Oncol; 2000 Sep; 18(17):3068-77. PubMed ID: 11001674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy.
    Bamias A; Efstathiou E; Moulopoulos LA; Gika D; Hamilos G; Zorzou MP; Kakoyiannis C; Kastritis E; Bozas G; Papadimitriou C; Dimopoulos MA
    Ann Oncol; 2005 Feb; 16(2):307-13. PubMed ID: 15668289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
    Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A
    Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
    Helke C; May M; Hoschke B
    Aktuelle Urol; 2006 Sep; 37(5):363-8. PubMed ID: 17004181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine doublets in advanced urothelial cancer.
    Stadler WM
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):15-9. PubMed ID: 11894003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5.
    Kim HD; Im HS; Kim JH; Jeong H; Yoon SK; Park I; Lee JL
    Cancer Res Treat; 2021 Oct; 53(4):1166-1173. PubMed ID: 33677847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.